Hauptseite > Publikationsdatenbank > Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia > print

001     188612
005     20210129215224.0
024 7 _ |a 10.1038/mp.2014.32
|2 doi
024 7 _ |a 1359-4184
|2 ISSN
024 7 _ |a 1476-5578
|2 ISSN
024 7 _ |a WOS:000351779300009
|2 WOS
024 7 _ |a altmetric:2329083
|2 altmetric
024 7 _ |a pmid:24798585
|2 pmid
037 _ _ |a FZJ-2015-01954
082 _ _ |a 610
100 1 _ |0 P:(DE-HGF)0
|a Kuhn, J.
|b 0
|e Corresponding Author
245 _ _ |a Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer’s dementia
260 _ _ |a London
|b Macmillan
|c 2015
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1426174810_7693
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 0
|2 EndNote
|a Journal Article
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |2 DRIVER
|a article
520 _ _ |a Cholinergic neurons of the medial forebrain are considered important contributors to brain plasticity and neuromodulation. A reduction of cholinergic innervation can lead to pathophysiological changes of neurotransmission and is observed in Alzheimer’s disease. Here we report on six patients with mild to moderate Alzheimer’s disease (AD) treated with bilateral low-frequency deep brain stimulation (DBS) of the nucleus basalis of Meynert (NBM). During a four-week double-blind sham-controlled phase and a subsequent 11-month follow-up open label period, clinical outcome was assessed by neuropsychological examination using the Alzheimer’s Disease Assessment Scale—cognitive subscale as the primary outcome measure. Electroencephalography and [18F]-fluoro-desoxyglucose positron emission tomography were, besides others, secondary endpoints. On the basis of stable or improved primary outcome parameters twelve months after surgery, four of the six patients were considered responders. No severe or non-transitional side effects related to the stimulation were observed. Taking into account all limitations of a pilot study, we conclude that DBS of the NBM is both technically feasible and well tolerated.
536 _ _ |0 G:(DE-HGF)POF3-571
|a 571 - Connectivity and Activity (POF3-571)
|c POF3-571
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de
700 1 _ |0 P:(DE-HGF)0
|a Hardenacke, K.
|b 1
700 1 _ |0 P:(DE-HGF)0
|a Lenartz, D.
|b 2
700 1 _ |0 P:(DE-HGF)0
|a Gruendler, T.
|b 3
700 1 _ |0 P:(DE-HGF)0
|a Ullsperger, M.
|b 4
700 1 _ |0 P:(DE-HGF)0
|a Bartsch, C.
|b 5
700 1 _ |0 P:(DE-HGF)0
|a Mai, J. K.
|b 6
700 1 _ |0 P:(DE-Juel1)131714
|a Zilles, K.
|b 7
|u fzj
700 1 _ |0 P:(DE-Juel1)131672
|a Bauer, Andreas
|b 8
|u fzj
700 1 _ |0 P:(DE-Juel1)138474
|a Matusch, A.
|b 9
|u fzj
700 1 _ |0 P:(DE-HGF)0
|a Schulz, R-J
|b 10
700 1 _ |0 P:(DE-HGF)0
|a Noreik, M.
|b 11
700 1 _ |0 P:(DE-HGF)0
|a Bührle, C. P.
|b 12
700 1 _ |0 P:(DE-HGF)0
|a Maintz, D.
|b 13
700 1 _ |0 P:(DE-HGF)0
|a Woopen, C.
|b 14
700 1 _ |0 P:(DE-HGF)0
|a Häussermann, P.
|b 15
700 1 _ |0 P:(DE-HGF)0
|a Hellmich, M.
|b 16
700 1 _ |0 P:(DE-HGF)0
|a Klosterkötter, J.
|b 17
700 1 _ |0 P:(DE-HGF)0
|a Wiltfang, J.
|b 18
700 1 _ |0 P:(DE-HGF)0
|a Maarouf, M.
|b 19
700 1 _ |0 P:(DE-Juel1)131867
|a Freund, Hans-Joachim
|b 20
|u fzj
700 1 _ |0 P:(DE-HGF)0
|a Sturm, V.
|b 21
773 _ _ |0 PERI:(DE-600)1502531-7
|a 10.1038/mp.2014.32
|g Vol. 20, no. 3, p. 353 - 360
|n 3
|p 353 - 360
|t Molecular psychiatry
|v 20
|x 1476-5578
|y 2015
856 4 _ |u https://juser.fz-juelich.de/record/188612/files/FZJ-2015-01954.pdf
|y Restricted
909 C O |o oai:juser.fz-juelich.de:188612
|p VDB
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)131714
|a Forschungszentrum Jülich GmbH
|b 7
|k FZJ
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)131672
|a Forschungszentrum Jülich GmbH
|b 8
|k FZJ
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)138474
|a Forschungszentrum Jülich GmbH
|b 9
|k FZJ
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)131867
|a Forschungszentrum Jülich GmbH
|b 20
|k FZJ
913 0 _ |0 G:(DE-HGF)POF2-333
|1 G:(DE-HGF)POF2-330
|2 G:(DE-HGF)POF2-300
|a DE-HGF
|b Gesundheit
|l Funktion und Dysfunktion des Nervensystems
|v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases
|x 0
913 0 _ |0 G:(DE-HGF)POF2-89571
|1 G:(DE-HGF)POF2-89570
|2 G:(DE-HGF)POF3-890
|a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|v Connectivity and Activity
|x 1
913 1 _ |0 G:(DE-HGF)POF3-571
|1 G:(DE-HGF)POF3-570
|2 G:(DE-HGF)POF3-500
|a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|v Connectivity and Activity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2015
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
915 _ _ |0 StatID:(DE-HGF)0110
|2 StatID
|a WoS
|b Science Citation Index
915 _ _ |0 StatID:(DE-HGF)0111
|2 StatID
|a WoS
|b Science Citation Index Expanded
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Thomson Reuters Master Journal List
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
915 _ _ |0 StatID:(DE-HGF)0310
|2 StatID
|a DBCoverage
|b NCBI Molecular Biology Database
915 _ _ |0 StatID:(DE-HGF)1030
|2 StatID
|a DBCoverage
|b Current Contents - Life Sciences
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
915 _ _ |0 StatID:(DE-HGF)9915
|2 StatID
|a IF >= 15
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-1-20090406
|k INM-1
|l Strukturelle und funktionelle Organisation des Gehirns
|x 0
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-1-20090406
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)INM-2-20090406

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21